Biofrontera vs Verrica Pharmaceuticals
BFRI and VRCA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BFRI and VRCA compare
Verrica Pharmaceuticals is the larger company, worth 4.8 times as much as Biofrontera ($67.2M against $13.9M).
Verrica Pharmaceuticals grew revenue faster over the last twelve months (106% versus 17.8% for Biofrontera).
Biofrontera keeps more of each dollar of sales as profit, with a net margin of −13.8% compared with −103% at Verrica Pharmaceuticals.
Biofrontera scores higher on the StockData Score (9 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BFRI | VRCA |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $67.2M |
| Share price | $0.938 | $3.91 |
| Change, 1 year | −9.9% | 1.0% |
| Change, 5 years | −98.2% | −96.6% |
| Beta (5Y) | 1.02 | 1.09 |
| Employees | 92 | 76 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 2.2× |
| P/B | 2.3× (better) | 15.6× |
| FCF yield | −57.0% | – |
| Growth | ||
| Revenue growth (TTM) | 17.8% | 106% (better) |
| Revenue growth, 5Y average | 17.2% | – |
| Profitability | ||
| Operating margin | −14.2% (better) | −93.6% |
| Net margin | −13.8% (better) | −103% |
| FCF margin | −17.2% | – |
| Return on equity | −988% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −7.6× |
| Current ratio | 1.18 | 1.45 (better) |
| Altman Z-score | −6.18 (better) | −13.66 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 19.7% | 27.1% |
| Held by insiders | 23.6% | – |
| Insider net buying, 12 months | – | $211K |
Go deeper
- BFRI stock overview
- BFRI income statement
- BFRI valuation and score
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.